Auteurs Girard CA, Lecacheur M, Ben Jouira R, Berestjuk I, Diazzi S, Prod'homme V, Mallavialle A, Larbret F, Gesson M, Schaub S, Pisano S, Audebert S, Mari B, Gaggioli C, Leucci E, Marine JC, Deckert M, Tartare-Deckert S
Cancer research Mai 2020
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.Auteurs Diazzi S, Tartare-Deckert S, Deckert M
Cancers May 2020
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.Auteurs Imbert C, Montfort A, Fraisse M, Marcheteau E, Gilhodes J, Martin E, Bertrand F, Marcellin M, Burlet-Schiltz O, Peredo AG, Garcia V, Carpentier S, Tartare-Deckert S, Brousset P, Rochaix P, Puisset F, Filleron T, Meyer N, Lamant L, Levade T, Ségui B, Andrieu-Abadie N, Colacios C
Nature communications Jan 2020
Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.Auteurs Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, Montaudié H, Prod'Homme V, Tartare-Deckert S, Deckert M
Oncogene Juin 2019
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.Auteurs Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N
Molecular cancer therapeutics Fév 2019
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.Auteurs Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G
Theranostics Jan 2019
[Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].Auteurs Bertolotto C, Ohanna M, Ballotti R
Medecine sciences : M/S Déc 2018
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.Auteurs Didier R, Mallavialle A, Ben Jouira R, Domdom MA, Tichet M, Auberger P, Luciano F, Ohanna M, Tartare-Deckert S, Deckert M
Molecular cancer therapeutics Juil 2018
E2F1 inhibition mediates cell death of metastatic melanoma.Auteurs Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S
Cell death & disease Mai 2018
Rapid decay of engulfed extracellular miRNA by XRN1 exonuclease promotes transient epithelial-mesenchymal transition.Auteurs Zangari J, Ilie M, Rouaud F, Signetti L, Ohanna M, Didier R, Roméo B, Goldoni D, Nottet N, Staedel C, Gal J, Mari B, Mograbi B, Hofman P, Brest P
Nucleic acids research Avr 2018